Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology, Department of Clinical Medic...

Full description

Bibliographic Details
Main Authors: Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Format: Article
Language:English
Published: Dove Medical Press 2023-02-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
guselkumab
risankizumab
tildrakizumab
real world practice
psoriasis
anti-il-23
biologics.
Online Access:https://www.dovepress.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-result-peer-reviewed-fulltext-article-CCID

Internet

https://www.dovepress.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-result-peer-reviewed-fulltext-article-CCID

Similar Items